Madrigal Pharmaceuticals
MDGL
136 hedge funds and large institutions have $1.01B invested in Madrigal Pharmaceuticals in 2018 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 52 increasing their positions, 46 reducing their positions, and 42 closing their positions.
464% more call options, than puts
Call options by funds: $96.1M | Put options by funds: $17M
13% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 46
2.2% more ownership
Funds ownership: 56.15% → 58.36% (+2.2%)
13% less funds holding
Funds holding: 156 → 136 (-20)
45% less capital invested
Capital invested by funds: $1.85B → $1.01B (-$835M)
48% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 42
67% less funds holding in top 10
Funds holding in top 10: 3 → 1 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
+$65.9M |
| 2 |
JP Morgan Chase
New York
|
+$60.2M |
| 3 |
State Street
Boston,
Massachusetts
|
+$26.6M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$14.5M |
| 5 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
+$13M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$37.1M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
-$36.8M |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$28M |
| 4 |
O
OppenheimerFunds
New York
|
-$20.5M |
| 5 |
AC
Armistice Capital
New York
|
-$17.1M |
MDGL Hedge Fund Activity: Q4 2018 in Review
136 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Madrigal Pharmaceuticals (MDGL) for Q4 2018, worth a combined $1.01B — down 45% from $1.85B a quarter earlier.
Sellers outnumbered buyers: 42 funds closed out of MDGL and 22 opened new positions — a net loss of 20 holders — while 46 trimmed existing stakes and 52 added.
The largest buyer was HealthCor Management, adding an estimated $65.9M. The largest seller was T. Rowe Price Associates, cutting an estimated $37.1M.
- 136 institutional investors held Madrigal Pharmaceuticals (MDGL) as of Q4 2018, down from 156 in Q3 2018.
- Funds reported $1.01B of Madrigal Pharmaceuticals stock for Q4 2018, down 45% quarter-over-quarter.
- 22 funds opened new Madrigal Pharmaceuticals positions in Q4 2018 and 42 closed out, a net change of -20 holders.
- The largest Madrigal Pharmaceuticals buyer in Q4 2018 was HealthCor Management, an estimated $65.9M added.
- The largest Madrigal Pharmaceuticals seller in Q4 2018 was T. Rowe Price Associates, an estimated $37.1M sold.
Based on aggregated 13F filings for Q4 2018.